Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion LUNG-3
CTR20254994Phase 3Active
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zongertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Disease-free survival (DFS) by investigator assessment. Started Jan 2026; status: active.
02
Drugs
zongertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20254994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254994.